Interviews

Pushkar Mukewar

Founder & CEO

Drip Capital

2026-03-10

MSMEs will play a critical role in India’s growth toward a $4–5 trillion economy.

Mr Sudarshan Jain

Secretary-General

Indian Pharmaceutical Alliance

2026-03-10

Instead of only “Made in India”, we should be known as “Made and Innovated in India”.

Nisha Dutt

Managing Director & CEO

Subex

2026-03-10

And increasingly, all of them are being delivered through artificial intelligence, because fraud has ceased to be a crime of opportunity. It has become a crime of industrial scale, and rule-based detection systems are no longer sufficient to contain it.

Dr. Mohamed Adil A.A

Managing Director

Bangalore Bioinnovation Centre

2026-03-10

The focus is not only on scaling technologies but on making scale-up economically viable within India while maintaining international quality standards.

Dr. Mahesh Bhalgat

Group CEO

Veeda Lifesciences

2026-03-09

The challenge now is advancing toward innovation and moving up the value chain—being willing to build these capabilities organically rather than expecting them to be transferred.

Mr. Deepak Chand Thakur

Chairman and Managing Director

NPST

2026-03-09

Banks, as regulated institutions, are focused on stability, managing deposits, lending, compliance, and systemic risk. Fintechs, on the other hand, are optimised for speed, customer experience, and problem-solving at the last mile.What was missing was a strong, scalable bridge between these two worlds.

Sanjay Agarwal

Founder, MD & CEO

AU Small Finance Bank

2026-03-09

Large banks operate through heavy processes; agility sometimes suffers. At our size, we can offer speed, personalised structuring, and sharper execution, while now matching broader product capabilities through the universal platform.

Alison Moore

CEO

Codexis

2026-03-06

Estimates suggest that by 2030 the industry may need to manufacture between 10 and 30 metric tons of siRNA, which is a huge step up and underpins the strong interest in new, scalable manufacturing platforms like ECO Synthesis.

Kathleen Coviello

Chief Economic Transformation Officer

New Jersey Economic Development Authority (NJEDA)

2026-02-27

New Jersey’s signature programme is the Net Operating Loss (NOL) program, which allows companies to turn losses into cash — a lifeline for early-stage life science firms.

Serge Saxonov

Co-Founder & CEO

10x Genomics

2026-02-27

Fundamentally, if you are not analysing tissues at single-cell resolution and, for tissues, with spatial context, you are throwing away most of the biological signal.

Pagina 1 din 212